About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
Not Voodoo

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
Realizations in Biostatistics
ChemSpider Blog
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Eye on FDA
Chemical Forums
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa

Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
Gene Expression (I)
Gene Expression (II)
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net

Medical Blogs
DB's Medical Rants
Science-Based Medicine
Respectful Insolence
Diabetes Mine

Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem

Politics / Current Events
Virginia Postrel
Belmont Club
Mickey Kaus

Belles Lettres
Uncouth Reflections
Arts and Letters Daily
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« Business Note: Random Promotion, Anyone? | Main | Pushing Onwards with CETP: The Big Money and the Big Risks »

November 18, 2011

Two From Glaxo's Old Days

Email This Entry

Posted by Derek

Two of the scientists behind Glaxo's rise have passed away recently, within a couple of weeks of each other. There's John Bradshaw, who joined Allen and Hanburys in 1971. He was the chemist who discovered Zantac (ranitidine) in 1976. Later, he moved into computational chemistry and made a key insight that led to the discovery of Salmeterol, one of the two drugs that make up Advair. Not many people have ever put their fingerprints on two bigger compounds in one medicinal chemistry career.

And closely intertwined with these projects, and with at least five others that made it to market, was pharmacologist Sir David Jack, who'd joined Allen and Hanburys ten years earlier. Remarkably, he kept up his research in the field after retirement, and a compound he championed (RPL554) is even now in clinical trials from Verona Pharma.

Discoveries, never forget, don't make themselves. They're made by people, and it's well worth paying attention to people who've made several. Odds are that they are (or were) doing something right. . .

Comments (7) + TrackBacks (0) | Category: Drug Industry History


1. Hap on November 18, 2011 10:18 AM writes...

Will anyone get the chance to make several? It seems like being the discoverer of a big drug only means that people notice and commiserate when your company lays you off.

Permalink to Comment

2. Robur on November 19, 2011 3:26 AM writes...

Really good to see this post.

It does seem more important than ever to recognise the difference that individual scientists can make in this Industry.

I'd argue that it's up to all of us to believe we can continue to do so. Yes, times are very hard, but then again no harder than the nature of our task. We should never lose sight of the opportunity we have to change the world.

Permalink to Comment

3. anon on November 19, 2011 8:32 AM writes...

Never had the chance to meet either, but wonder what they would think of what is going on in the current organization R&D. Will be interesting to see how Vallence's plan works out for the redeployed - have heard "trust us" WAY too often lately, seriously thinking of getting out of chemistry if it appears to be a reasonable path forward.

Chemistry in US/EU appears to be a dying field - too big of a market in China/India for companies to ignore, labor costs cheaper, and lesser environmental restrictions. Just the current reality.

Permalink to Comment

4. cadder on November 19, 2011 9:28 AM writes...

wow, a computational chemist making key insights to the discovery of salmeterol... i can't believe my eyes... perhaps a good answer to your previous "old med chem view" post on modeling

hail hail the lucky ones

Permalink to Comment

5. Anonymous on November 20, 2011 6:55 AM writes...

What a contrast between these guys who really shaped the industry for the better and the likes of Slaoui, Vallance, Baldoni et al who are now in control! It's sad to see how such an important industry has been brought down by mega-mergers, poor management and runawy egos and arrogance!

Permalink to Comment

6. Anonymous on November 30, 2011 9:52 AM writes...

Baldoni is the biggest Jerk of all.

Permalink to Comment

7. Anonymous on November 30, 2011 9:52 AM writes...

Baldoni is the biggest Jerk of all.

Permalink to Comment


Remember Me?


Email this entry to:

Your email address:

Message (optional):

The Last Post
The GSK Layoffs Continue, By Proxy
The Move is Nigh
Another Alzheimer's IPO
Cutbacks at C&E News
Sanofi Pays to Get Back Into Oncology
An Irresponsible Statement About Curing Cancer
Oliver Sacks on Turning Back to Chemistry